SCLXW | Scilex Holding Company Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.2950 - 0.2999
52 Week Range	0.2950 - 0.2999
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	534
Average Volume	N/A
Shares Outstanding	577,627,118
Market Cap	177,296,818
Sector	Healthcare
Industry	Drug Manufacturers - General
IPO Date	N/A

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	N/A
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	113
Country	USA
Website	SCLXW

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

SCLXW's peers: AMRN, NAMSW, EUDAW

*Chart delayed

Analyzing fundamentals for SCLXW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see SCLXW Fundamentals page.

Watching at SCLXW technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on SCLXW Technicals page.